Trial Profile
Phase I study of combination chemotherapy with erlotinib and S-1 as the 2nd or 3rd-line treatment in platinum-refractory advanced non-small cell lung cancer (TORG0808).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Aug 2020
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 15 Aug 2020 Results from two studies ( UMIN000003421 & UMIN000003422 ) published in the Investigational New Drugs
- 09 Nov 2011 New trial record